Monthly Archives: February 2010

US and Europe At Risk from Substandard Medicines

Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank. When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to […]
Posted in Biotech, Emerging Markets, Europe, Global, Guest Blog, Regulatory, Safety | Tagged , , , , , , , , , , , | Leave a comment

Merck, Lilly, Pfizer: One for All and All for One

Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well. Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, […]
Posted in Strategy | Tagged , , , , , , , | 1 Comment

FDA and GSK on the Hunt for Stolen Drugs

Image by Johnny Grim via Flickr We typically don’t get emails from FDA  asking for information about stolen goods with massive bold letters, but that’s what just came into our inbox. Looks like a transport truck containing a mix of GlaxoSmithKline’s pharmaceutical and over-the-counter medications was jacked in Puerto Rico on January 29, and the […]
Posted in FDA, News | Tagged , , , , , , | 1 Comment

Obama Reveals Healthcare Reform Plan

Image via Wikipedia The health reform proposal unveiled by the White House on Feb. 22, 2010 retains a number of provisions that directly affect drug coverage and industry revenues. The plan highlights that it will close the Medicare drug benefit “doughnut hole” by 2020 to make drugs more affordable to the elderly. Seniors will get […]
Posted in News, Regulatory | Tagged , , , , , | 4 Comments

Europe: Of Apes and Ombudsmen

Guest blog by Reflector, Pharm Exec Europe‘s Brussels correspondent. This column has frequently drawn attention to the complexities of getting anything done in Europe. A brilliant researcher can explore visionary horizons, an ambitious entrepreneur can offer a package of goods or services of inestimable value, but the degree of control and regulation becomes more intense […]
Posted in Europe, Global, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta